New Phase 3 Monotherapy Study of Sirukumab Versus Humira ® And Sirukumab Data In An Anti-Tnf Refractory Population Reported In The Treatment Of Moderately To Severely Active Rheumatoid Arthritis

Anti-Interleukin-6 Monoclonal Antibody Sirukumab Efficacy and Safety Findings from SIRROUND-H and SIRROUND-T Trials Presented for the First Time at the 2016 ACR/ARHP Annual Meeting
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news